CA-EXPERIAN
28.8.2024 15:01:27 CEST | Business Wire | Press release
Experian has been recognized as a Leader by Liminal, a leading market and competitive intelligence company, in its 2024 Link Index for Account Takeover (ATO) Prevention in Banking. The report provides a detailed analysis of the ATO prevention market and identifies the top companies and emerging players at the forefront of innovation in authentication, fraud prevention, and identity.
The report cited Experian’s strategic approach, market presence, and CrossCore® capabilities with especially high ratings. It commented, “The company’s comprehensive fraud detection and identity management solutions, including the CrossCore orchestration faculty, are trusted by businesses worldwide to protect against a wide range of fraud types – 97% of surveyed financial service practitioners were familiar with the Experian brand.”
“We help our bank clients protect their customers and assets against the ever-increasing sophistication of AI-supported fraud attacks where traditional security measures can no longer keep up as well as our clients would like them to,” said Alex Lintner, Chief Executive Officer, Experian Software Solutions. “The dramatic rise in digital accounts over the past few years has created enormous financial risk for banks and consumers. In response, we are constantly innovating ‘protective AI’ technology to offer the industry’s most effective identity verification and fraud prevention solutions — and we’re pleased our efforts have been acknowledged by Liminal.”
Experian also ranked highly in both the Strategy and Product Execution categories. “Our diverse range of services provides a valuable asset for banks faced with the three-pronged challenge of trying to simultaneously solve for authentication, identity and fraud prevention,” added Lintner. “Our solutions provide excellent protection against phishing and social engineering through advanced behavioral biometrics and analytics as well as Bot detection capabilities.”
The report highlighted the value and features of Experian CrossCore, which combines risk‑based authentication, identity proofing and fraud detection into a single, state-of-the-art cloud platform. Regarding CrossCore, the report stated that it provides “a fully featured toolkit that leverages a wide range of capabilities for highly accurate and scalable ATO prevention” and is “one of the most comprehensive product capability suites among the vendors we profiled.”
“We’re pleased to recognize Experian for its strong leadership position in authentication, fraud prevention and identity protection,” said Travis Jarae, CEO at Liminal. “Account takeover poses a major risk in the banking sector, where unauthorized access through phishing, malware or stolen credentials leads to misuse of accounts for theft and other malicious activities — resulting in significant financial losses and the undermining of customer trust.”
About Liminal
Liminal is a technology company that empowers businesses with actionable market and competitive intelligence for go-to-market and sales enablement. Our state-of-the-art platform combines the precision of AI with human expertise to deliver unparalleled access to proprietary data, in-depth analysis, and curated insights, enabling executives to make informed decisions, enhance productivity, and drive growth. We tackle critical focus areas with targeted solutions for fraud and identity, cybersecurity, trust and safety, financial crimes compliance, and privacy and consent management. Trusted by industry leaders and innovators at top public and private companies and investment firms to navigate market complexities and thrive with confidence and clarity. Get access with a Link account or learn more at www.liminal.co.
About Experian
Experian is a global data and technology company, powering opportunities for people and businesses around the world. We help to redefine lending practices, uncover and prevent fraud, simplify healthcare, deliver digital marketing solutions, and gain deeper insights into the automotive market, all using our unique combination of data, analytics and software. We also assist millions of people to realize their financial goals and help them to save time and money.
We operate across a range of markets, from financial services to healthcare, automotive, agrifinance, insurance, and many more industry segments.
We invest in talented people and new advanced technologies to unlock the power of data and innovate. As a FTSE 100 Index company listed on the London Stock Exchange (EXPN), we have a team of 22,500 people across 32 countries. Our corporate headquarters are in Dublin, Ireland. Learn more at experianplc.com.
Experian and the Experian marks used herein are trademarks or registered trademarks of Experian and its affiliates. Other product and company names mentioned herein are the property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828673485/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
